Leafly

APRIL 6, 2020

Prescription CBD tincture Epidiolex is coming to more patients. The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly. Cost: $32,500 per year.

DEA 128

DEA CBD Tincture Patients 128

Project CBD

NOVEMBER 8, 2021

Psilocybin, the psychedelic mushroom extract, has been fast-tracked by the FDA to treat depression, but doctors still can’t use it in their practice.

DEA 150

DEA Patients Extraction 150

Cannabis Law Report

AUGUST 12, 2021

Drug Enforcement Administration’s (DEA) refusal to accommodate state and federal right to try laws. US DEA , No. RTT laws permit certain patients who have been diagnosed with life-threatening diseases or conditions access to investigational medications not yet approved for general use by the U.S. 21-70544 (9th Cir.),

DEA 105

DEA Medicine Food Patients 105

Cannabis Law Report

FEBRUARY 24, 2023

DEA extends many telemedicine flexibilities adopted during the COVID-19 PHE with appropriate safeguards WASHINGTON – Today, the Drug Enforcement Administration announced proposed permanent rules for the prescribing of controlled medications via telemedicine, expanding patient access to critical therapies beyond the scheduled end of the COVID-19 (..)

DEA 52

DEA Therapy Access Patients 52

Americans for Safe Access

APRIL 19, 2022

When we started Americans for Access, we were facing paramilitary style raids from the DEA, only 8 states had passed laws creating criminal exemptions for medical cannabis patients, the DEA was still saying that cannabis was a gateway drug and there was no legal access anywhere!

DEA 243

DEA Access Patients Law 243

Cannabis Law Report

DECEMBER 7, 2021

On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. The DEA’s notice provides the industry with an opportunity to provide insight and feedback that may help shape the new regulations.

DEA 52

DEA Patients Therapy Access 52

WeedAdvisor

JULY 4, 2019

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety.

DEA 111

DEA Research and Development Clinical Trials Cultivation 111

The Cannigma

JUNE 14, 2021

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We BRC) told The Cannigma this week. Junk’ cannabis ‘ill-suited for clinical trials’. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

MJ Business Attorneys

JUNE 29, 2018

Epidiolex is the first drug the FDA has approved that contains a substance derived from marijuana, and it is also the first drug approved by the FDA to be used to treat patients with Dravet syndrome. Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. In the recent case Hemp Industries Associations v.

DEA 113

DEA CBD Pharmaceutical Research and Development 113

Cannabis Law Report

JUNE 3, 2021

A Seattle palliative care physician has filed a lawsuit against the DEA, contesting its decision to ban psilocybin for use by terminally ill patients. Background of the Case. Read more .

DEA 98

DEA Access Clinical Trials Patients 98

NORML

JANUARY 12, 2024

"It is significant for these health agencies to acknowledge publicly, for the first time, what many patients and advocates have known for decades: that cannabis is a safe and effective therapeutic agent for tens of millions of Americans."

DEA 315

DEA Marijuana Patients Cannabis 315

Cannabis Law Report

FEBRUARY 5, 2022

Drug Enforcement Administration (DEA) this week challenging the government’s Schedule I classification of psilocybin, the main psychoactive component of psychedelic mushrooms. Seattle Doctor Files DEA Petition To Reschedule Psilocybin For Medical Use. Marijuana Moment. As part of the suit, attorneys general from eight U.S.

DEA 52

DEA Patients Marijuana 52

Cannabis Law Report

MAY 25, 2021

Marijuana Moment reports A bipartisan group of attorneys general from eight U.S. states and the District of Columbia has sided… Read More.

DEA 97

DEA Patients Marijuana 97

SpeedWeed

SEPTEMBER 4, 2021

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. Some states in the U.S.

DEA 52

DEA Research and Development Clinical Trials Extraction 52

Veriheal

JUNE 22, 2021

While the federal government still holds medical cannabis or even recreational cannabis from the people clinging to years of draconian prohibition, they are allowing certain individuals to work with the DEA and FDA to study antimicrobial properties of cannabinoid therapies being applied to fighting bacteria such as MRSA.

DEA 65

DEA Access Therapy Cannabinoids 65

SpeedWeed

MAY 18, 2021

Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. For years, NIDA and the DEA have promised to open up the sourcing of federally-approved research cannabis. DEA finally relents.

DEA 52

DEA Research and Development Data Cannabis 52

Cannabis Law Report

OCTOBER 4, 2021

One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

JUNE 3, 2019

Plaintiffs in the case, including medical marijuana patients, told the 2nd U.S. Circuit Court of Appeals that the DEA’s refusal to reschedule cannabis damaged their health and that the federal agency should remove cannabis from Schedule 1. Federal appeals court to DEA: Reconsider marijuana’s Schedule 1 status.

DEA 59

DEA Patients Marijuana Cannabis 59

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . Most recently the FDA awarded MMJ International Holdings ?

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

NOVEMBER 20, 2021

he Alabama State Board of Medical Examiners Thursday announced draft rules to govern how physicians can recommend medical cannabis to eligible patients. The draft rules would require physicians to obtain an annual certification permit from the Alabama Board of Medical Examiners if they want to recommend a patient to use medical cannabis.

Patients 52

Patients DEA Dispensary Conditions 52

Cannabis Law Report

FEBRUARY 8, 2022

The law, which has some doctors saying they have stopped working with medical cannabis patients altogether, requires that patients obtain written “certifications” from doctors in order to access marijuana concentrates over a new daily limit. It is unknown how many doctors have decided to stop working with cannabis patients.

Patients 52

Patients Legislation Concentrates DEA 52

Marijuana Lawyer Blog

JANUARY 12, 2019

As our Los Angeles marijuana patient attorneys can explain, the crux of the argument by plaintiffs of the claim, first filed in 2017, is that the designation ignores the merits of the drug for medicinal purposes. Defendants are acting-Attorney General Matthew Whitaker, the acting director of the DEA and the federal government.

DEA 40

DEA Patients Epilepsy Medicine 40

WeedAdvisor

JUNE 1, 2019

The court, citing concerns over marijuana’s Schedule I status and its impact on medical users who need it most, essentially issued an ultimatum to the DEA. Like a child who does not want to clean his or her room, the DEA simply refuses to take any major action, despite the whirlwind of reforms surrounding them on a daily basis.

DEA 55

DEA Marijuana History Cannabis 55

United Patients Group

JANUARY 15, 2023

However, the DEA and FDA still consider CBD a drug regulated under the Schedule I classification. The DEA definition of a Schedule 1 substance is : Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Book a consultation today.

THC 114

THC CBD DEA Cannabinoids 114

NORML

JANUARY 17, 2019

As the result of a lawsuit, DEA Administrative Law Judge Mary Ellen Bittner in 2007 ruled that expanding the pool of federally licensed providers would be “in the public interest.” The agency ultimately rejected her decision. Click here to send a message to your federal lawmaker and urge them to support the measure. .

Clinical Trials 230

Clinical Trials Legislation DEA Strains 230

Cannabis Law Report

MAY 10, 2022

Activists staged a demonstration outside of the Drug Enforcement Administration (DEA) headquarters in Virginia on Monday, demanding that the agency allow terminally ill patients to access psilocybin therapy. Patients, veterans and key advocates participated in the demonstration. Marijuana Moment reports. aeidinger) May 9, 2022.

DEA 52

DEA Therapy Access Patients 52

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Americans for Safe Access

JUNE 6, 2019

In July 2017, four medical cannabis patients joined other advocates in filing a lawsuit against the federal government in the U.S. Drug Enforcement Administration (DEA) to reschedule cannabis, before filing suit. District Court for the Second District of New York. The plaintiffs in the case (originally Washington v.

DEA 204

DEA Patients Cannabis 204

Cannabis Law Report

SEPTEMBER 4, 2021

Circuit Court of Appeals to order the federal Drug Enforcement Authority to offer a way for terminally ill patients to try psilocybin, the active chemical in hallucinogenic mushrooms, to treat their anxiety and depression. Forty-one states have passed such laws.

Clinical Trials 109

Clinical Trials Law DEA Patients 109

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). The RTT Act.

DEA 52

DEA Clinical Trials Policy Research and Development 52

The Blunt Truth

DECEMBER 15, 2023

The DEA sends a letter to Georgia pharmacies. GEORGIA Earlier this fall, we noted that independent pharmacies in Georgia would begin offering low THC oil to medical marijuana patients. Well, apparently the Drug Enforcement Administration (DEA) noted that as well, and they didn’t take kindly to it.

DEA 59

DEA Legislation Legalization Consumption 59

Cannabis Law Report

NOVEMBER 2, 2022

Drug Enforcement Administration and the legal team representing terminally ill patients petitioning for access to psilocybin-assisted therapy. In late September, the DEA denied an official petition requesting that the agency look into rescheduling psilocybin from Schedule I to Schedule II.

Microdosing 52

Microdosing DEA Therapy Access 52

United Patients Group

APRIL 3, 2023

A recommendation from a physician is simply permission (‘recommendation’) for the patient to use cannabis, which can be obtained in any state where medical marijuana is legal. Epidiolex, an FDA-approved medication containing CBD (cannabidiol), has been listed as Schedule 5 by the DEA since June 25th, 2019.

DEA 52

DEA Patients Conditions Cannabis 52

Americans for Safe Access

APRIL 2, 2019

The Americans for Safe Access 2019 Unity Conference, themed The Price of Being a Medical Cannabis Patient, featured over a hundred patients from all over America visiting their representatives in Congress and the Senate to promote the Medical Cannabis Control Act of 2019.

Access 100

Access DEA Policy Patients 100

MedicalJane

JUNE 29, 2018

Although this is exciting for many advocates of the plant, many patients that are suffering from ailing health conditions are left wondering what this means for them, and how exactly all of these changes will impact their healthcare options. Do you qualify for medical cannabis? Do you qualify for medical cannabis? Check it out here.

Patients 83

Patients Legalization Conditions Treatment 83

Cannabis Law Report

JULY 7, 2021

Pennington, who focuses on federal appeals and regulatory issues, is co-counsel on several high-profile cases against the DEA regarding cannabis research, hemp, and psychedelics. Circuit), a pending petition for review of DEA’s August 2020 Interim Final Rule purportedly implementing the 2018 Farm Bill’s amendments to the CSA.

DEA 111

DEA Hemp Cultivation Advocacy 111

FloridaMarijuana.net

JULY 8, 2018

PTSD patients lack the necessary endocannabinoids to fill the receptor sites properly. Medical marijuana and cannabinoids can be used to treat a patient’s physical and psychological health, alleviating the debilitating symptoms of PTSD. The study has received full approval from the FDA, DEA, and Institutional Review Boards (IRBs).

Strains 190

Strains Indica Hybrid Research and Development 190